| 标题： | 早期乳腺癌新辅助治疗临床实践指南 2022. V1(CSBrS-Guideline-23) |
| title： | Clinical practice guideline for neoadjuvant therapy in early-stage breast cancer (CSBrS-Guideline-23) |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 标准指南 |
| classification： | Standard guideline |
| 领域： | 综合 |
| field： | Comprehensive guideline |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 早期乳腺癌保留乳房手术临床实践指南以中国乳腺疾病专业临床医生为适用对象。 |
| Guide users： | Clinicians specializing in breast diseases in China. |
| 证据分级方法： | 证据分级方法采用GRADE分级系统结合中国的临床研究，等级分为I、II、III和IV类，以量化编撰委员会专家对证据可靠性的评估。为了使这些指南在中国的临床实践中可用，专家组优先选择指南评估系统中所示的I类和II类证据 |
| Evidence grading method： | The level of evidence grading system was developed by referring to the GRADE system combined with findings in clinical studies in China. The levels are classified as Category I, II, III, and IV to quantify the evaluation of the reliability of the evidence by experts on the compiling committees. To make these guidelines accessible in clinical practice in China, the expert panel preferentially selected Category I and II evidence, as indicated in the guideline evaluation system |
| 制定单位： | 中华医学会外科学分会乳腺外科学组 |
| Formulating unit： | Chinese Society of Breast Surgery |
| 注册时间： | 2022-01-23 |
| Registration time： | |
| 注册编号： | IPGRP-2022CN044 |
| Registration number： | |
| 指南制订的目的： | 针对具有适应证的早期乳腺癌选择新辅助治疗可带来临床获益已经获得广泛共识，新辅助治疗的目的和意义也有了更丰富的内容,包括适应证、治疗方案、疗效评价都有了更多的临床证据。中华医学会外科学分会组织乳腺疾病相关专业专家针对乳腺癌新辅助治疗问题进行文献收集与讨论，参照GRADE系统对相关证据进行评价，旨在为中国乳腺外科相关专业医师提供借鉴和参考 |
| Purpose of the guideline： | There has been widespread consensus that neoadjuvant therapy can bring clinical benefits in early breast cancer. The purpose and significance of neoadjuvant therapy have also been enriched, including more indications, treatment options and therapeutic evaluation. The Chinese Society of Breast Surgery organized related experts to discuss the neoadjuvant therapy of breast cancer, and evaluated the relevant evidence with reference to the GRADE system, aiming to provide reference for China's breast surgeons. |
